Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
Kristine M Erlandson, Laurel Gustafson, Julia E Johnson...
https://pubmed.ncbi.nlm.nih.gov/42419889/Actively Recruiting
Led by Massachusetts General Hospital · Updated on 2026-05-19
100
Participants Needed
2
Research Sites
24 weeks
Total Duration
People living with HIV often face earlier declines in physical function and develop frailty more quickly than the general population. Frailty involves symptoms like reduced activity, fatigue, slowness, weakness, and weight loss. Although exercise can help improve physical function in people with HIV, its effects are often less pronounced and harder to maintain over time. This research aims to evaluate whether the medication tesamorelin, combined with exercise, can improve physical function and muscle health in adults with HIV. Participants will take part in a 24-week intervention where half will receive daily injections of tesamorelin, a growth hormone-releasing hormone analogue approved for treating abdominal fat in HIV, while the other half will receive a placebo injection. All participants will also engage in a semi-supervised home-based exercise program guided by an exercise coach. After this phase, there will be a 24-week extension period during which participants will stop the study drug and supervised exercise but will be encouraged to continue exercising independently. During the study, researchers will assess physical function, muscle mass and quality, quality of life, exercise adherence, and self-efficacy. Key measurements include changes in chair stand time, walk time, muscle strength, and frailty status from baseline to week 24. Safety and continued effects after stopping treatment will also be monitored. Total participation lasts at least 48 weeks, allowing evaluation of both treatment effects and follow-up outcomes.
CONDITIONS
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
L
Lindsay T. Fourman, MD
K
Kristine M. Erlandson, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Massachusetts General Hospital
Lead Sponsor
University of Colorado, Denver
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Tesamorelin + exercise | Placebo + exercise | Exercise alone |
|---|---|---|---|
| What the option is | Tesamorelin is a growth hormone‑releasing hormone analogue given daily by injection alongside a home‑based semi‑supervised exercise programme. | An identical placebo injection is given daily alongside the same home‑based semi‑supervised exercise programme. | Current standard supportive care is exercise‑based programmes to improve physical function and frailty in older people with HIV. |
| Role in the trial | Experimental treatment arm. | Placebo control arm. | Usual care comparator not randomized in trial. |
| Primary study purpose | To test whether adding tesamorelin to exercise improves physical function in frail, sedentary adults with HIV. | To serve as placebo control for evaluating effect of tesamorelin plus exercise. | Represents current exercise‑based supportive care for physical function and frailty management. |
| How it is delivered | Daily subcutaneous injection of tesamorelin plus home‑based semi‑supervised exercise. | Daily subcutaneous injection of placebo plus home‑based semi‑supervised exercise. | Exercise‑only supportive programmes typically involve supervised or semi‑supervised exercise sessions aimed at improving function. |
| Evidence maturity | Efficacy for physical function outcomes is under investigation in this randomized controlled trial with assessments at Weeks 24 and 48. | Provides control comparison to assess effect of tesamorelin beyond exercise alone. | Supervised or semi‑supervised exercise interventions have demonstrated functional and frailty improvements in older adults with HIV. |
| Important risks | Safety risks under investigation; tesamorelin may affect glucose metabolism, and participants with elevated HbA1c are excluded. | Placebo injections generally have no pharmacologic risk; injection‑site reactions possible. | Exercise is generally low‑risk but may carry musculoskeletal or cardiovascular stress, and should be tailored to ability. |
| Important limitations | Functional benefits are not yet known; long‑term sustainability beyond follow‑up is uncertain. | Placebo plus exercise may underestimate the effect of exercise alone, without growth hormone analogue. | Access, adherence, and supervision levels vary widely in real‑world practice compared with trial conditions. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 24 weeks
Participants receive daily subcutaneous injections of Tesamorelin or placebo along with a home-based semi-supervised exercise program to improve physical function.
Weekly visits for up to 24 weeks
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kristine M Erlandson, Laurel Gustafson, Julia E Johnson...
https://pubmed.ncbi.nlm.nih.gov/42419889/Massachusetts General Hospital
Lead Sponsor
University of Colorado, Denver
Collaborating Sponsor